Introduction
Tumor necrosis factor-alpha (TNF-a) has pluripotent effects on tumorigenesis and tumor progression, and it is produced by tumor and tumor microenvironment (Goillot et al., 1992; Komori et al., 1993; Elbaz and Mahmoud, 1994; Liu et al., 1998; Suganuma et al., 1999; Montesano et al., 2005; Rivas et al., 2008) . The effect of TNF on angiogenesis, however, is controversial (FraterSchroder et al., 1987; Leibovich et al., 1987; Sato et al., 1987) . In cell culture, the effect of TNF on angiogenesis depends on the concentration and the duration of the treatment (Frater-Schroder et al., 1987; Leibovich et al., 1987; Sato et al., 1987; Fajardo et al., 1992; Slowik et al., 1993) . In endothelial cells (ECs), TNF increases the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin (IL)-8 (Yoshida et al., 1997) . In addition, impaired TNF signaling in ECs was associated with enhanced apoptotic response in cutaneous microvasculature in adult tissue (Fajardo et al., 1992) .
TNF exerts its function via binding to p55 (TNFR1) and p75 (TNFR2). Both p55 and p75 bind to TNF receptor-associated factor 1 and 2 (TRAF1 and TRAF2) (Rothe et al., 1994; Sethi et al., 2008) , thus providing a mechanism for shared activity between the two receptors. On the other hand, the cytoplasmic domains of p55 and p75 are significantly different and these receptors are reported to trigger divergent signaling pathways upon interaction with TNF (Jacobsen et al., 1994; Rothe et al., 1994; Barbara et al., 1996; Sethi et al., 2008) . The intracellular signaling involving p55 has been well deciphered. Studies have shown that p55 activates both apoptosis and cell survival signaling pathway, and the pro-apoptotic effects of p55 are related to the death domain on its cytoplasmic part of the receptor (Jacobsen et al., 1994; Barbara et al., 1996; Bhardwaj and Aggarwal, 2003) . Inversely, p55, via activating NF-kB, increases the expression of genes that in turn suppress TNF-mediated apoptosis (Jacobsen et al., 1994; Barbara et al., 1996; Bhardwaj and Aggarwal, 2003) . Compared with p55, few signaling pathways and functions of p75 have been elucidated, especially in the context of tumor angiogenesis (FraterSchroder et al., 1987; Slowik et al., 1993) . Unlike p55, the cytoplasmic domain of p75 lacks the death domain (Mukhopadhyay et al., 2001) . Studies have shown that in ECs, Bmx/Etk (endothelial/epithelial tyrosine kinase) binds to p75 constitutively. TNF stimulation induces reciprocal phosphorylation between p75-bound Bmx/ Etk and VEGFR2, which leads to the activation of the Akt pathway and in turn results in EC migration and angiogenesis (Zhang et al., 2003) . Studies from our laboratory have shown that p75 signaling promotes ischemia-induced angiogenesis via modulation of several angiogenic growth factors in mice (Goukassian et al., 2007) .
We hypothesize that p75 signaling may be essential for the angiogenic and survival processes in tumor tissue and blocking p75 signaling may affect tumor cell survival. We also investigated p75-mediated effects on p38 (MAPK) activation in bone marrow (BM)-derived endothelial progenitor cells (EPCs). BM-derived EPCs are known to be critical regulators of the angiogenic switch in progression of micro-metastasis to lethal macro-metastasis (Gao et al., 2008; Rafii and Lyden, 2008) , and tumor-derived TNF signaling had been linked in vivo to differentiation of myeloid progenitors cells to 'byphenotypic' myeloid/ECs (Li et al., 2009) . In this study, we identified the role of functional p75 signaling in BM-derived EPCs in vitro and in the context of tumor angiogenesis and tumor growth in vivo.
Results

TNFR2/p75 KO microenvironment does not support
Lewis lung carcinoma (LLC) and B16 melanoma tumor growth After 21 days of inoculation, tumor (LLC) volumes were larger in WT and double-KO (Dbl-KO) mice compared with p75KO mice (Supplementary Figure S1) . A similar growth was observed in all three genotypes between day 0-7 ( Figure 1a ). Compared with day 7, tumors in WT and Dbl-KO mice became B370% (Po0.02) and B1030% (Po0.008) larger on days 14 and 21, respectively, whereas in p75KO mice, tumors became only B180% (Po0.05) and B420% (Po0.01) larger on days 14 and 21, respectively. Kinetics of tumor growth and tumor volumes in Dbl-KO mice were comparable with WT mice with no statistical difference at any time point. Compared with WT and Dbl-KO mice, tumor growth in p75KO mice was reduced by B30% (Po0.05) on day 14 and B50% (Po0.001) on day 21 (Figure 1a) . These results suggest that the absence of signaling through p75, but not both TNF receptors (for example, Dbl-KO) in tumor tissue microenvironment inhibits tumor growth.
B16 mouse metastatic melanoma tumor growth was evaluated in WT and TNFR2/p75 mice, as well (Supplementary Figure S2) . Tumor growth kinetics revealed that between days 0-7 tumors grew similarly in WT vs p75 mice. Compared with day 7, melanoma tumors in WT mice became B1195% larger (twelvefold) on day 14, whereas at the same time period tumor growth was inhibited in p75KO mice by more than two times (Po0.02) on day 14 (only 474% increase between day 7 vs day 14). These results indicate that in the absence of the signaling via TNFR2/p75, at least in the tumor tissue microenvironment, melanoma growth can be inhibited B2.5-fold. Note that in these experiments B16 cells were unaltered (so-called 'wild type') and the tumor growth inhibition was predominantly dependent on unsupportive host tissue in p75KO mice. LLC ( Figure 1a ) and B16 melanoma xenograft studies (Supplementary Figure S2) taken together suggest that this may be a common response of vascularized tumors of different origin, at least in part, due to decreased tumor angiogenesis.
TNF expression is similar in the tumor tissue from WT and p75KO mice Immunostaining showed that the intensity of TNF staining in tumor or normal tissue (2 cm distant from tumor) was not different between WT and p75KO mice ( Figure 1b and Supplementary Figures S3A and B) . However, compared with normal skin (Supplementary Figure S3B) , TNF expression was Bten and ninefold (Po0.001) higher in tumor tissue from WT and p75KO mice, respectively. Enzyme-linked immunosorbent assay (ELISA) of tumor homogenates confirmed that TNF levels were similar in tumor tissue from WT vs p75KO mice (1010±166 vs 976±262 pg/ml, P ¼ NS) (Figure 1c ).
VEGF expression and capillary density are decreased, and apoptosis is increased in tumors from p75KO mice Compared with WT tumors, the intensity of VEGF immunostaining in tumor tissue from p75KO mice was decreased more than 50% (Po0.001). (Figure 1d and Supplementary Figure S4A) . Accordingly, ELISA of tumor homogenates showed B40% (Po0.002) decrease in VEGF levels in the tumor tissue from p75KO mice (Figure 1e ). CD31 immunostaining was significantly decreased in tumors from p75KO mice (80% decrease, Po0.001, Figure 1f and Supplementary Figure S4B ). Fluorescence-activated cell sorting analysis revealed a 41% (Po0.045) decrease in CD31 ( þ ) cell in the whole-tumor tissue from p75KO vs WT mice (Figure 1g ). Terminal transferase dUTP nick end labeling (TUNEL) staining was increased B40% (Po0.05) in tumor tissue from p75KO mice (Figure 1h and Supplementary Figure S4C ). 
TNFR2/p75 is required for the activation of p38 MAPK in BM-derived EPCs
In cultured BM-derived EPCs obtained from WT mice and in cultured LLCs, TNF treatment activated p38 MAPK in a time-dependent manner (Figures 5a and b and e and f), whereas in EPCs obtained from p75KO mice, TNF-mediated p38 activation was significantly weaker (B0.4-fold, P ¼ NS, Figures 5c-d) . These results suggest that (a) signaling via TNF receptor p75 is necessary for proper p38 activation in BM-derived EPCs and (b) that p38 is constitutively activate in LLCs and there is significant TNF-mediated p38 activation in LLCs.
TNF-mediated apoptosis is increased in TNFR2/p75 knockdown (KD) LLCs
To further substantiate the clinical implications of our findings in p75KO mice implanted with unaltered tumor cells, and due to the fact that we cannot create p75 KO host humans, but with current drugs and technologies, we can inhibit/block efficiently p75 receptor in the whole-tumor tissue (tumor cells, EC, fibroblasts, inflammatory cells and BM-derived cells); we performed a series of experiments using p75 receptor KD cancer cells. We generated p75 receptor KD LLCs (p75KD/ LLCs) using short-hairpin RNA technology (Supplementary Materials and Methods). qRT-PCR data of percent inhibition of p75 receptor in stably transfected p75KD/LLCs is presented in Supplementary Figure S8 . p75KD or LLCs (plasmid combinations 1 þ 2 and 1À4) showed B74 or 90% inhibition of p75 receptor expression, respectively (Supplementary Figure S8) . Compared with control, scrambled plasmid-transfected LLCs, TNF treatment induced B56% and 90% apoptotic cells (cells in sub-G0/G1 population) (Riccardi and Nicoletti, 2006) in p75KD/LLCs (1 þ 2) and p75KD/LLCs (1-4), respectively ( Figure 6a ). Increase in apoptotic cells was in direct correlation with percent inhibition of p75 receptor (Figure 6a and Supplementary Figure S8 ). Compared with control, p75KD/LLCs (1 þ 2 and 1À4) showed significant TNF-mediated decrease in the expression of VEGFA (0.75-3.5-fold), HGF (2.5-9-fold), PLGF (3-15-fold), CXCR4 (5-20-fold) ( Figures  6b-e, grey bars) . The constitutive levels of these genes were also decreased in non-treated p75KD/LLC cells (Figures 6b-e, black bars) . Thus, the highest degree of The densitometry values of Hsp90ab1 and BAS2C genes were used as internal control. An arbitrary cutoff was set at 1.6 (up or down). We assigned an arbitrary cutoff thresholds for fold changes at 1.6 (here and elsewhere).
TNFR2/p75 inhibition for cancer treatment SP Sasi et al apoptosis ( Figure 6a ) and decrease in the expression of angiogenic factors and Sdf-1a receptor CXCR4 (Figures 6b-e) were observed in cells with the lowest p75 receptor expression level (Figure 6a and Supplementary Figure  S8 ), which strongly corroborates our findings in mouse tumor tissue (Figures 1d-h, and Figures 2a and b) .
Discussion
It is well known that TNF is continuously produced in tumors and tumor microenvironment and this endogenous tumor-produced TNF induces tumor angiogenesis and promotes tumor development and spread (Goillot Phospho p38 Figure 5 Signaling through TNFR2/p75 is required for proper activation of p38 MAPK in EPCs. (a, c, e) Representative images of phospho-p38 (P-p38) and total-p38 (T-p38) western blot analysis in WT and p75KO EPCs and unaltered LLCs. (b, d, f) Quantification p38 protein level and phosphorylation using densitometric analysis of P-p38 band intensity after adjusting for actin (not shown) and T-p38 band intensity. Band intensity at time 0 for each cell type was set at 100% and percent change over 60 min was calculated. Results represent data from three independent experiments. Statistical significance was assigned when Po0.05. (Hohenberger et al., 2003) . TNFR1/p55 and TNF2/p75, receptors of TNF, have opposing TNF-mediated effects. TNFR1/p55 is known to mediate cytotoxic effects of TNF and cell death . However, p75 is implied in cell protective effects of TNF (Slowik et al., 1993; Jacobsen et al., 1994; Vandenabeele et al., 1995; Barbara et al., 1996) in endothelial and hematopoietic lineage cells (Jacobsen et al., 1994; Hohenberger et al., 2003) . The role of TNFR2/p75 in mediating tumor growth and angiogenesis is unclear. In order to clarify the role of TNFR2/p75 in mediating TNF-induced angiogenic survival and apoptosis processes in tumor tissue, we utilized TNFR2/p75 KO mice to remove signaling through p75 receptor in tumor-microenvironment and shorthairpin RNA to KD p75 expression in tumor cells. In view of the fact that the divergent TNF effects has been attributed to TNF concentration, duration of exposure (Fajardo et al., 1992) and also type of targeted cells , we analyzed TNF levels in tumor tissues from WT vs p75KO mice. There was a 9-10-fold increase in TNF levels in LLC tumor implants vs normal skin in both WT and p75KO mice and the TNF level in tumors from WT and p75KO mice were not different. These results indicate that decreased capillary density in tumors from p75KO mice were not caused by lack or different concentration of TNF in tumors due to mice genotype; rather it may be due to increased cytotoxic TNF signaling through unopposed p55 receptor in tumor tissue microenvironment . Moreover, augmented levels of apoptosis in tumor tissues from p75KO mice underscored our hypothesis that absence of signaling via p75 TNFR2/p75 inhibition for cancer treatment SP Sasi et al receptor in the tumor microenvironment affects survival processes within the tumor tissue, which creates a hostile environment for tumor and EC cells. Tumor growth is angiogenesis dependent (Folkman, 1971; Gimbrone et al., 1972; Hanahan and Folkman, 1996) . VEGF, a critical growth factor in angiogenesis, is known to be regulated by TNF (Yoshida et al., 1997; Eisenthal et al., 2003) . Similar to earlier studies in models of post-natal neovascularization (Luo et al., 2006; Goukassian et al., 2007) , we observed a significant reduction in VEGF expression in tumor tissue from p75KO vs WT mice. This suggests that intact p75 signaling in tumor microenvironment may have an important role in tumor angiogenesis through positive regulation of VEGF expression (Goukassian et al., 2007; Meng et al., 2010) . Indeed, VEGF decreases were associated with a significant reduction in capillary network in tumors from p75KO vs WT mice. Our findings suggest that inhibition of tumor angiogenesis due to decreased expression of VEGF and other angiogenic growth factors and cytokines (PLGF, CXCl2, IL1b and others.) may be the primary mechanism of tumor growth inhibition in p75KO mice.
TNF, via p75, elicits potent EC-activating cytokine and growth factor signaling (Ryuto et al., 1996; Yoshida et al., 1997) that induces EC/EPC survival, migration, recruitment and incorporation into new tumor microvasculature and angiogenesis (Lyden et al., 2001; Peters et al., 2005; Santarelli et al., 2006) ; whereas activation of p55 signaling by TNF leads to inhibition of EC migration and increase in EC apoptosis (Madge and Pober, 2001) . VEGF has been shown to mobilize BMderived EPCs in murine models and in humans (Asahara et al., 1999; Kalka et al., 2000) . In p75KO mice, decreased TNF-induced putative angiogenic signaling (TNF-NF-kB-VEGF), may lead to subsequent decreases in either mobilization, recruitment, homing or survival of BM-derived EPCs in the p75KO tumor tissue (Lyden et al., 2001; Peters et al., 2005; Santarelli et al., 2006) . In agreement with these previous reports, we showed that there was a significant decrease in the incorporation of recruited EPCs into functional capillary network in tumors from p75KO mice, which suggests an additional mechanism of impaired angiogenesis in p75KO tumor tissue.
This study further showed that a significant number of angiogenesis genes (p38 MAPK 14, VEGFA and VEGFB amongst others), as well as pro-angiogenic growth and transcription factors, and cytokines were decreased in LLC and B16 tumors from p75KO mice. These factors are directly involved in the regulation of Akt, Erk1/2 MAPK (p42/44 MAPK), p38 MAPK and NF-kB pathways that are known to promote tumor survival, proliferation, migration and angiogenesis processes (Mukhopadhyay et al., 2001; Gupta et al., 2003) . It is conceivable that decreases in p38 MAPK and two of VEGF isoforms (a and b) are directly downstream of p75 signaling, and are not affected by organspecific tumor origin, at least in two murine tumor models of lung adenocarcinoma (LLC) and malignant melanoma (B16). The rest of angiogenesis genes that were regulated differently in LLC and B16 tumors were either specific for the type of the tumor origin (lung vs melanoma) and/or are further downstream of TNFmediated signaling, such as NF-kB activation (Cxcl2, IL18, IL1b and IL12a) (Kohno and Kurimoto, 1998; Park et al., 2001; De Plaen et al., 2006) , which (NFkB) we reported to be decreased in p75KO EPCs in vitro (Goukassian et al., 2007) . These findings strongly suggest that blocking p75 receptor signaling in tumor microenvironment and/or tumor cells may negatively affect tumor growth through inhibition of additional pathways beyond VEGF signaling. This phenomenon may be common also for tumors of other origin that require substantial vascularization but this, however, remains to be tested.
Absence of p75 receptor in the host tissue minimally affected expression of genes in cancer pathways microarray, suggesting that different microenvironment does not significantly affect cancer pathways gene expression in the whole-tumor tissue. Further experimentation that rigorously determine gene expression changes in cancer cells as well as host microenvironment cells (that is, stromal cells, ECs, immune cells from peripheral blood, BM-derived progenitor cells and others.) will be necessary to confer causality of gene expression changes to microenvironmental/host tissue cues and the vice versa.
Taken together, our findings suggest that blocking p75 TNF receptor in tumor cells affects their survival and tumor-promoting properties of the tumor cells themselves (for example, tumor angiogenesis). This underscores a feasibility that one drug may have a dual anti-tumor effect aimed toward tumor microenvironment, as well as tumor cells. Therefore, we would like to suggest that selective inhibition of TNFR2/p75 signaling in tumor tissue with an antecedent increase in TNF (in tumor tissue) or delivery of small non-toxic exogenous recombinant TNF may present a novel cancer monotherapy or, most likely, part of combination therapy that will help to sensitize tumor cells and tumor ECs to cytotoxic effects of currently in-use anti-tumor (chemotherapy, radiotherapy, anti-angiogenic and others.) therapies.
Materials and methods
Mouse tumor models, cell culture and tumor inoculation Six to eight weeks old WT (C57BL/6J-control of the mixed C57BL/6 and 129 stains background defined by the vendor as N10F34, meaning that these two strains were backcrossed 10 times (N10 is number of backcross generations) and inbreed 34 times (F34 is number of filial or inbreeding generations)), p75KO (B6. 129S2-Tnfrsf1b tm1Mwm /J) and p55KO/p75KO (B6. 129S-Tnfrsf1a tm1Imx Tnfrsf1b tm1Imx /J) (Dbl KO) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Mice were handled in accordance with the guidelines set by the IACUC at St Elizabeth's Medical Center (Boston, MA, USA). LLC cells were obtained from ATCC (Manassas, VA, USA). After trypan blue exclusion (95% viability), 5 Â 10 5 LLC/mouse were re-suspended in 100 ml 1 Â PBS, mixed with 100 ml of growth factor reduced and phenol free Matrigel (BD Biosciences, Bedford, MA, USA) and injected subcutaneously into right flanks. Tumor growth was monitored using electronic calipers on days 7, 14 and 21. Immunostaining, imaging and analyses For immunostainings, tumors were bisected in half, embedded in OCT compound (Tissue-Tek, Torrance, CA, USA) and snap-frozen in liquid nitrogen. Cryosections (6-8 mm) of WT and p75KO tumors were fixed in acetone (4 1C) for 10 min (Goukassian et al., 2007) and processed for various immunostaining. Topro-3 was used to visualize nuclei (Invitrogen, Carlsbad, CA, USA). Primary anti-TNF-a rabbit polyclonal (Abcam, Cambridge, MA, USA) and rhodamine-conjugated goat anti-rabbit secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were used for detection of TNF expression in tumors and normal skin (2-3 mm away from tumors). Primary anti-VEGFA rabbit polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and TRITC-conjugated goat anti-rabbit secondary antibodies were used for detection of VEGF expression. Anti-CD31 primary (BD Pharmingen, San Jose, CA, USA) and Alexa Fluor 555 goat anti-rat secondary antibodies (Invitrogen) were used to determine vascular network in tumors. To analyze apoptotic processes, tumor tissues were stained with ApopTag Fluorescein in situ Apoptosis (TUNEL) Kit (Chemicon International, Temecula, CA, USA). All immunostainings were imaged using laser scanning confocal microscope (Meta510, ZEISS, Thornwood, NY, USA). Graphs represent pooled data of mean pixel intensity in 7-8 fields of 176 400 mm 2 /mouse from at least five animals/genotype using NIH ImageJ program (v1.40, NIH, Bethesda, MD, USA).
Enzyme-linked immunosorbent assay (ELISA) Levels of VEGF and TNF in the whole-tumor tissue were assessed by ELISA (RayBiotech, Norcross, GA, USA). The plates were read using the Tecan Spectra model 96 Well Microplate Reader (MTX Lab Systems, Vienna, VA, USA).
Fluorescence-activated cell sorting analysis of tumor-associated CD31 positive cells Whole tumors from WT and p75KO mice were collected on day 14 post-inoculation, minced into small pieces and digested in enzymatic medium containing Collagenase A (Roche, Indianapolis, IN, USA). Cell suspension was stained with rat anti-mouse CD31 antibody and 7AAD viability staining solution (both, eBiosciences, San Diego, CA, USA). Percent of tumor-associated CD31 ( þ ) cells were analyzed by FACSCanto II (BD, Franklin Lakes, NJ, USA). The data was analyzed using Summit v4.0 software (DakoCytomation, CA). (Supplementary Materials and Methods).
BM transplant mouse model
To track BM-derived cells into tumor tissues, 3 Â 10 6 donor BM mononuclear cells from GFPpositive WT and p75KO mice were injected through tail vein into lethally irradiated syngeneic WT or p75KO mice as described by us previously (Goukassian et al., 2007) . On day 28 post-BM transplant, WT/ WT-GFP and p75KO/p75KO-GFP BM transplant mice were inoculated with LLCs into the right flank and tumor growth was monitored. Mice were killed and tumors were harvested 21 days after the inoculation. To evaluate patent/ functional vessels, mice were injected with biotinylated BS1/ lectin (Invitrogen) 30 min before being killed as described (Coleman et al., 2010) . Tumors were harvested and processed for immunostaining using Cy5-labeled streptavidin (Invitrogen) to visualize BS1/lectin-stained, thus, perfused vessels.
Gene array analysis and qRT-PCR A p-shaped piece of tumor tissue was bisected from WT and p75KO mice and homogenized. Total RNA was isolated from tumors (RNeasy Mini Kit, QIAGEN, Valencia, CA, USA) and converted to cRNA using the SuperArray TrueLabeling-AMP 2.0 (SuperArray, Frederick, MD, USA). The gene array membranes were processed according to the manufacturer (Oligo GEArray Kit, SuperArray). Gene array membranes were exposed to Amersham Hyperfilms, and films were analyzed using Bio-Rad densitometry machine and software. qRT-PCRwas performed on five genes (Ang-1, Ang-2, Mmp2, Hif1-a, CXCL2) to confirm gene array analysis results. Supplementary Table S1 contains specific forward and reverse primer sequences. The samples were analyzed using Applied Biosystems 7300 Real Time PCR machine and software.
TNF treatment and fluorescence-activated cell sorting analysis and qRT-PCR of p75KD/LLCs p75 KD LLC (p75KD/LLC) cell lines transfected with 1 þ 2 and 1 þ 2 þ 3 þ 4 p75 short-hairpin RNA plasmids (Supplementary Materials and Methods) were treated with 80 ng/ml mrTNF (BD Biosciences). Twenty four hours post-TNF treatment, cells were stained with 18 mg propidium iodide (SIGMA, St Louis, MO, USA) in 1 ml 1 Â PBS (MediaTech, Herndon, VA, USA) with 8 mg RNAse-A (SIGMA) for 30 min and analyzed for DNA content using fluorescent activated cell sorter (Becton-Dickinson, San Jose, CA, USA) (Goukassian et al., 2007) . The percentage of apoptotic cells (the sub-G0/G1 population) was determined using CellQuest Pro (BD Biosciences). mRNA expression of angiogenic factors and receptors was determined by qRT-PCR. For specific forward and reverse primers sequences for each gene (VEGF-A, HGF, PLGF, Ang-1, Ang2 and CXCR4) see Supplementary Table S1 .
Western blot analysis WT and p75KO BM-derived EPCs were isolated from tubular bones, selected ex vivo, and used between days 6 and 8 after the initial plating as described in our laboratory (Goukassian et al., 2007) . LLCs were maintained as separate culture according to ATCC recommendations. At 60-70% confluence medium was removed and fresh media was added with or without 80 ng/ml mrTNF. Cells were harvested 30 and 60 min after TNF and no-TNF (control) treatments and processed for western blot analysis for detection of total p38 (T-p38), and phosphorylated p38 (P-p38) protein using antibodies against phospho-or total-specific p38 MAPK (Cell Signaling Technology, Danvers, MA, USA). Anti-b-actin staining was used as loading control. ECL kit (Amersham Biosciences; GE, Piscataway, NJ, USA) was used for immunodetection.
Statistical analysis
All results were expressed as mean±s.e.m. Statistical analyses were performed using Student's t-test (unpaired) and ANOVA/ANCOVA by Fisher's PLSD (StatView,
